Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price18.36 USD
Fair value19.82
Ethical score70.0/100
Our investment reviews on this name
2026-08-25Read Distribution21.05-12.8% to today ✓
2026-07-02Read Accumulation27.60-33.5% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Core Scientific, Inc. holds its Markdown at $18.36. Consolidating, no directional conviction, held for 15 days.
As held on the ledger · 2026-09-21
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 15 days
Price at the screen
$18.36
Valuation
N/A trailing · 131.14 forward price to earnings
Values screen
FAIL· score 70.0
Beta
5.49
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
49.52%
Below 33%
Interest-bearing debt is 49.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
27.62%
Below 49%
Money owed to the company is 27.6% of assets, under the 49% limit.
Pass
Revenue purity
1.03%
Below 5%
Only 1.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. A 8.0% margin of safety to the base estimate.
Third-party analyst targets: 16 covering, consensus Strong Buy. The average target sits +96% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Crypto power plays rarely deliver steady profits
Picture a warehouse packed with humming servers that mine digital coins one month and host corporate data the next. Core Scientific supplies the electricity, cooling and floor space for exactly that mix. Revenue is rising fast at 45 percent, yet the business still posts zero profit margins and carries a forward multiple above seventy times earnings.
That combination leaves little room for error. The shares already sit six percent above our fair value and the market is pricing in flawless execution in a sector known for sudden power-price spikes and coin-price crashes. Strong analyst targets exist, but they sit well ahead of any visible earnings runway.
Risk sits in the absence of a proven moat and the total dependence on volatile digital-asset demand. Even with an ethical screen pass, the valuation offers no margin of safety today. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CORZ trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 57% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (14 analysts) rates it strong buy, with a mean price target of $32.
2026-07-25Accumulation$20.94-24.1%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 24.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 57% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (14 analysts) rates it strong buy, with a mean price target of $32.
2026-07-18Accumulation$27.60+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 57% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (14 analysts) rates it strong buy, with a mean price target of $32.
2026-07-03Accumulation$27.60+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$27.60Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.